<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01125865</url>
  </required_header>
  <id_info>
    <org_study_id>SCH-2010-04</org_study_id>
    <nct_id>NCT01125865</nct_id>
  </id_info>
  <brief_title>Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture</brief_title>
  <official_title>Uncovered Self-expandable Metal Stent Versus DoubleLayer Plastic Stent for Malignant Hilar Stricture: a Prospective Randomized Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soon Chun Hyang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soon Chun Hyang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall median survival of nonresectable malignant hilar obstruction in most series has
      been less than 6 months. Most patients with malignant hilar obstruction present with advanced
      disease, making palliative endoscopic drainage the principal therapeutic option. However, the
      optimal endoscopic management strategy is contentious. Almost all of the published data
      comparing plastic and metallic stents relate to distal tumors (those of the pancreas, common
      bile duct and ampulla). Stent patency, complication rates, and cost-effectiveness have
      favored metallic stents when compared with plastic stents in patients with distal malignant
      obstruction expected to live at least 3 to 6 months.

      There are few comparative study as to whether self-expanding metallic or plastic stent,
      especially DLS (double layer plastic stent) are preferable in the technical success, stent
      patency, and cost-effectiveness for palliating malignant hilar obstruction.

      The study was designed to compare the the technical success, stent patency, and
      cost-effectiveness of self-expandable metal stent and DLS in patients with malignant hilar
      obstruction.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stent patency</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Interval time (d) from stent insertion to occlusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause complications</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Early or Late complications
asymptomatic hyperamylasemia
pancreatitis (mild/moderate/severe)
cholecystitis
cholangitis
recurrent jaundice
Internal migration
external migration
occlusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Total Cost for SEMS and DLS group
ERCP cost
Total ERBD cost (DLS or metal)
Total hospitalization cost
Cost for session x No. of session
Total (DLS vs. metal)cost /session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>within 24 hr after stent insertion</time_frame>
    <description>Successful insertion of bilateral or unilateral stent insertion.
Time to adequate expansion (70% of maximal expanded diameter was dilated state) in metal stent ≤ 24 hrs
No stent migration within 24 hrs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bile Duct Obstruction</condition>
  <condition>Klatskin's Tumor</condition>
  <arm_group>
    <arm_group_label>SEMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Self-expandable metallic stent will be inserted for the malignant hilar obstruction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DLS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DoubleLayer plastic stent (Olympus) will be inserted for malignant hilar obstruction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SEMS insertion</intervention_name>
    <description>Self-expandable metallic stent will be inserted for malignant hilar obstruction.</description>
    <arm_group_label>SEMS</arm_group_label>
    <other_name>Bona stent</other_name>
    <other_name>TaeWoong stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DLS insertion</intervention_name>
    <description>DoubleLayer plastic stent will be inserted for malignant hilar obstruction.</description>
    <arm_group_label>DLS</arm_group_label>
    <other_name>Olympus DoubleLayer stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years old

          -  Patient with malignant hilar obstruction

        Exclusion Criteria:

          -  No written informed consent

          -  Patient with uncorrectable severe coagulopathy

          -  Indication for surgical operation

          -  Karnofsky score &lt; 60%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Do Hyun Park, MD</last_name>
    <phone>+82-2-3010-3180</phone>
    <email>dhpark@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tae Hoon Lee, MD</last_name>
    <phone>+82-41-570-3662</phone>
    <email>thlee9@lycos.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Soon Chun Hyang University Cheonan Hospital</name>
      <address>
        <city>Cheonan</city>
        <state>23-20 Bongmyung-dong</state>
        <zip>330-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Hoon Lee, MD</last_name>
      <phone>+82-41-570-3662</phone>
      <email>thlee9@lycos.co.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Pusan Paik Hospital</name>
      <address>
        <city>Pusan</city>
        <state>Busanjin-gu, Gaegeum-dong</state>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung Sik Choi, MD</last_name>
      <phone>+82-51-890-6114</phone>
      <email>cwj1225@medigate.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Pungnap-2dong, Songpagu</state>
        <zip>388-1</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Do Hyun Park, MD</last_name>
      <phone>+82-2-3010-3180</phone>
      <email>dhpark@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <state>Seo-gu, Dunsan-dong</state>
        <zip>302-799</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Woo Cha, MD</last_name>
      <phone>+82-42-611-3052</phone>
      <email>swcha@eulji.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Tringali A, Mutignani M, Perri V, Zuccalà G, Cipolletta L, Bianco MA, Rotondano G, Philipper M, Schumacher B, Neuhaus H, Schmit A, Devière J, Costamagna G. A prospective, randomized multicenter trial comparing DoubleLayer and polyethylene stents for malignant distal common bile duct strictures. Endoscopy. 2003 Dec;35(12):992-7.</citation>
    <PMID>14648409</PMID>
  </reference>
  <reference>
    <citation>Wagner HJ, Knyrim K, Vakil N, Klose KJ. Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial. Endoscopy. 1993 Mar;25(3):213-8.</citation>
    <PMID>7686100</PMID>
  </reference>
  <reference>
    <citation>de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999 Oct 28;341(18):1368-78. Review.</citation>
    <PMID>10536130</PMID>
  </reference>
  <reference>
    <citation>Yeoh KG, Zimmerman MJ, Cunningham JT, Cotton PB. Comparative costs of metal versus plastic biliary stent strategies for malignant obstructive jaundice by decision analysis. Gastrointest Endosc. 1999 Apr;49(4 Pt 1):466-71.</citation>
    <PMID>10202060</PMID>
  </reference>
  <reference>
    <citation>Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc. 1998 May;47(5):354-62.</citation>
    <PMID>9609426</PMID>
  </reference>
  <reference>
    <citation>Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet. 1992 Dec 19-26;340(8834-8835):1488-92.</citation>
    <PMID>1281903</PMID>
  </reference>
  <reference>
    <citation>Prat F, Chapat O, Ducot B, Ponchon T, Pelletier G, Fritsch J, Choury AD, Buffet C. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc. 1998 Jan;47(1):1-7.</citation>
    <PMID>9468416</PMID>
  </reference>
  <reference>
    <citation>Cheng JL, Bruno MJ, Bergman JJ, Rauws EA, Tytgat GN, Huibregtse K. Endoscopic palliation of patients with biliary obstruction caused by nonresectable hilar cholangiocarcinoma: efficacy of self-expandable metallic Wallstents. Gastrointest Endosc. 2002 Jul;56(1):33-9.</citation>
    <PMID>12085032</PMID>
  </reference>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>March 9, 2011</last_update_submitted>
  <last_update_submitted_qc>March 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tae Hoon Lee</name_title>
    <organization>Soon Chun Hyang University Cheonan Hospital</organization>
  </responsible_party>
  <keyword>Malignant hilar stricture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Klatskin Tumor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

